Reed Elsevier nixes sale of b-to-b publishing division

Share this content:

Reed Elsevier has halted its long-planned sale of its business-to-business magazine arm Reed Business Information (RBI), citing “poor credit market conditions.”

“Whilst the short term outlook for RBI is challenging given the recent deterioration in economic outlook, we believe the business has significantly more value to our shareholders than could be realised in a transaction at this time,” explained Reed Elsevier CEO, Sir Crispin Davis, in a company statement.

For now, the company will hold on to RBI, managing it as a separate division within Reed Elsevier under the leadership of Keith Jones, who previously served as CEO of RBI UK. RBI's US arm is responsible for Publishers Weekly, which reported a total average qualified circulation of 21,946 for the 12 months ending June 30, 2007 but is no longer audited by the ABC; and the 34,550 daily circulation Variety, among others. Davis noted that RBI accounts for less than 10% of Reed Elsevier's operating profits and cash flows.

Reed Elsevier first mentioned plans to divest its b-to-b publishing arm in February. The move, which was part of a strategy to focus the business' growth on risk management and online workflow, also pushed the company to acquire insurance industry risk management firm ChoicePoint for upwards of $4 billion.

Since February, however, the publishing market has dried up, and willing buyers have become scarce. Reed Elsevier disclosed in November that it was in serious discussions with potential buyers, who remained unnamed, but no firm deals were made. A statement from Reed Elsevier noted that the company would look to divest RBI “in the medium term when conditions are more favourable.”

Loading links....

Next Article in Media/Circulation

Sign up to our newsletters

Company of the Week

SK&A is a leading provider of U.S. healthcare information solutions and databases. As part of IMS Health, SK&A researches and maintains contact and profiling data for over 2 million healthcare providers, including 800,000+ prescribers. SK&A's data supports research and marketing initiatives for life sciences, medical device, managed healthcare, direct marketing, publishing, education and more. SK&A's proprietary databases are telephone-verified twice per year from its world class Research Centers. SK&A enables multi-channel marketing and sets the standard for data quality and reliability. SK&A's customers include many of America's most recognized healthcare, publishing and pharmaceutical institutions.

Featured Listings